Peptide Mimotope Candidates for Otitis Media Vaccine


This technology describes peptide mimotopes of lipooligosaccharides (LOS) from nontypeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis that are suitable for developing novel vaccines against the respective pathogens, for which there are currently no licensed vaccines. The mimotopes not only immunologically mimic LOSs from NTHi and M. catarrhalis but will also bind to antibodies specific for the respective LOS. NTHi and M. catarrhalis are common pathogens that cause otitis media in children and lower respiratory tract infections in adults. The effectiveness of a vaccine could be increased by substitution of a LOS epitope with a peptide mimic. Preliminary experiments have shown that some of the mimic peptides conjugated to a carrier were as effective as their respective LOS-based vaccine in stimulating a humoral immune response in rabbits. A single consensus amino acid sequence was identified for M. catarrhalis, while four such sequences were identified for NTHi. Thus, the identified peptides are promising candidates for developing novel vaccines for NTHi or M. catarrhalis.

Potential Commercial Applications: Competitive Advantages:
Otitis media vaccine 


Development Stage:
In vivo data available

Inventors:

Xin-xing Gu (NIDCD)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 7,514,529 issued 2009-04-07
PCT Application No. PCT/US2004/001457
US Application No. 11/187,419

Collaboration Opportunity:

The NIDCD Vaccine Research Section is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Peptide vaccines derived from LOS of NTHi or M. catarrhalis. Please contact Marianne Lynch, a technology development specialist, at 301-594-4094 or lynchm2@mail.nih.gov for more information.


Licensing Contact:
Brian Bailey, Ph.D.
Email: bbailey@mail.nih.gov
Phone: 301-594-4094

OTT Reference No: E-344-2002-0
Updated: Jun 16, 2010